TISIDB

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Note=Localized in the cytoplasm and transported from the cytoplasm to the nucleus in some cells, possibly depending on the functional or developmental state of the cell.
Domain	PF07524 Bromodomain associated PF10406 Transcription factor TFIID complex subunit 8 C-term
Function	Transcription factor TFIID is one of the general factors required for accurate and regulated initiation by RNA polymerase II. Mediates both basal and activator-dependent transcription. Plays a role in the differentiation of preadipocyte fibroblasts to adipocytes, however, does not seem to play a role in differentiation of myoblasts. Required for the integration of TAF10 in the TAF complex. May be important for survival of cells of the inner cell mass which constitute the pluripotent cell population of the early embryo (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001701 in utero embryonic development GO:0001824 blastocyst development GO:0001832 blastocyst growth GO:0001833 inner cell mass cell proliferation GO:0009301 snRNA transcription GO:0016073 snRNA metabolic process GO:0032507 maintenance of protein location in cell GO:0034504 protein localization to nucleus GO:0042795 snRNA transcription from RNA polymerase II promoter GO:0045185 maintenance of protein location GO:0045444 fat cell differentiation GO:0045598 regulation of fat cell differentiation GO:0051235 maintenance of location GO:0051457 maintenance of protein location in nucleus GO:0051651 maintenance of location in cell GO:0072595 maintenance of protein localization in organelle GO:0098781 ncRNA transcription
Molecular Function	GO:0046982 protein heterodimerization activity
Cellular Component	GO:0000428 DNA-directed RNA polymerase complex GO:0005667 transcription factor complex GO:0005669 transcription factor TFIID complex GO:0016591 DNA-directed RNA polymerase II, holoenzyme GO:0030880 RNA polymerase complex GO:0044798 nuclear transcription factor complex GO:0055029 nuclear DNA-directed RNA polymerase complex GO:0061695 transferase complex, transferring phosphorus-containing groups GO:0090575 RNA polymerase II transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03022 Basal transcription factors
Reactome	R-HSA-74160: Gene Expression R-HSA-6807505: RNA polymerase II transcribes snRNA genes

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TAF8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TAF8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.66	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TAF8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.071	0.744
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.312	0.777
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.111	0.903
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.028	0.923
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.087	0.967
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.047	0.986
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.172	0.526
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.365	0.779
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.043	0.977
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.441	0.69
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.525	0.755
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.067	0.255

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TAF8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TAF8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TAF8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TAF8
Name	TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa
Aliases	FLJ32821; TAF(II)43; TBN; TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa; ......
Chromosomal Location	6p21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TAF8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TAF8